XOMA Royalty Corporation (NASDAQ:XOMA - Get Free Report) CEO Owen Hughes purchased 100,000 shares of the stock in a transaction on Thursday, December 4th. The stock was acquired at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the purchase, the chief executive officer directly owned 102,000 shares of the company's stock, valued at $2,555,100. The trade was a 5,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
XOMA Royalty Stock Up 1.9%
Shares of NASDAQ:XOMA opened at $30.49 on Tuesday. The stock's 50-day moving average price is $34.09 and its 200-day moving average price is $30.93. XOMA Royalty Corporation has a 12-month low of $18.35 and a 12-month high of $39.92. The stock has a market capitalization of $377.47 million, a P/E ratio of 41.20 and a beta of 0.94. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07.
XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.33). The company had revenue of $9.35 million during the quarter, compared to the consensus estimate of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. On average, equities analysts anticipate that XOMA Royalty Corporation will post -1.41 earnings per share for the current year.
Institutional Trading of XOMA Royalty
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in XOMA Royalty by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company's stock valued at $25,749,000 after purchasing an additional 29,298 shares during the period. Opaleye Management Inc. boosted its stake in shares of XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company's stock valued at $6,428,000 after purchasing an additional 2,044 shares in the last quarter. Woodline Partners LP increased its position in shares of XOMA Royalty by 16.5% during the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company's stock valued at $8,091,000 after buying an additional 29,715 shares during the period. Geode Capital Management LLC raised its stake in XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company's stock worth $5,132,000 after buying an additional 16,929 shares in the last quarter. Finally, Stonepine Capital Management LLC lifted its holdings in XOMA Royalty by 17.2% in the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company's stock worth $3,834,000 after buying an additional 22,330 shares during the period. Hedge funds and other institutional investors own 95.92% of the company's stock.
Analyst Ratings Changes
Several brokerages have weighed in on XOMA. Weiss Ratings reiterated a "hold (c)" rating on shares of XOMA Royalty in a research report on Tuesday, November 25th. Zacks Research lowered shares of XOMA Royalty from a "hold" rating to a "strong sell" rating in a report on Tuesday, November 18th. Finally, Wall Street Zen cut shares of XOMA Royalty from a "buy" rating to a "hold" rating in a research report on Saturday, November 15th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $69.50.
Check Out Our Latest Research Report on XOMA
About XOMA Royalty
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
